Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center

The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.(1) IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.